192 related articles for article (PubMed ID: 25472670)
21. MicroRNA signatures: novel biomarker for colorectal cancer?
Luo X; Burwinkel B; Tao S; Brenner H
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1272-86. PubMed ID: 21551242
[TBL] [Abstract][Full Text] [Related]
22. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
Zhang K; Wang YW; Wang YY; Song Y; Zhu J; Si PC; Ma R
Gene; 2017 Jul; 619():10-20. PubMed ID: 28359916
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal study on circulating miRNAs in patients after lung cancer resection.
Leidinger P; Galata V; Backes C; Stähler C; Rheinheimer S; Huwer H; Meese E; Keller A
Oncotarget; 2015 Jun; 6(18):16674-85. PubMed ID: 26078336
[TBL] [Abstract][Full Text] [Related]
24. The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer.
Chen WY; Zhao XJ; Yu ZF; Hu FL; Liu YP; Cui BB; Dong XS; Zhao YS
Int J Clin Exp Pathol; 2015; 8(6):7092-101. PubMed ID: 26261602
[TBL] [Abstract][Full Text] [Related]
25. Investigating intra-tumor heterogeneity and expression gradients of miR-21, miR-92a and miR-200c and their potential of predicting lymph node metastases in early colorectal cancer.
Jepsen RK; Novotny GW; Klarskov LL; Christensen IJ; Høgdall E; Riis LB
Exp Mol Pathol; 2016 Oct; 101(2):187-196. PubMed ID: 27565378
[TBL] [Abstract][Full Text] [Related]
26. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
27. Variability in microRNA recovery from plasma: Comparison of five commercial kits.
Brunet-Vega A; Pericay C; Quílez ME; Ramírez-Lázaro MJ; Calvet X; Lario S
Anal Biochem; 2015 Nov; 488():28-35. PubMed ID: 26271186
[TBL] [Abstract][Full Text] [Related]
28. Identification of a plasma four-microRNA panel as potential noninvasive biomarker for osteosarcoma.
Lian F; Cui Y; Zhou C; Gao K; Wu L
PLoS One; 2015; 10(3):e0121499. PubMed ID: 25775010
[TBL] [Abstract][Full Text] [Related]
29. Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression.
Li CY; Liang GY; Yao WZ; Sui J; Shen X; Zhang YQ; Peng H; Hong WW; Ye YC; Zhang ZY; Zhang WH; Yin LH; Pu YP
Clin Transl Oncol; 2017 Feb; 19(2):162-172. PubMed ID: 27173517
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.
Torres A; Torres K; Pesci A; Ceccaroni M; Paszkowski T; Cassandrini P; Zamboni G; Maciejewski R
Int J Cancer; 2013 Apr; 132(7):1633-45. PubMed ID: 22987275
[TBL] [Abstract][Full Text] [Related]
31. Circulating microRNA expression profiles in ovarian cancer.
Ayaz L; Çayan F; Balci Ş; Görür A; Akbayir S; Yıldırım Yaroğlu H; Doğruer Unal N; Tamer L
J Obstet Gynaecol; 2014 Oct; 34(7):620-4. PubMed ID: 24911418
[TBL] [Abstract][Full Text] [Related]
32. Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis.
Zhang MY; Li SH; Huang GL; Lin GH; Shuang ZY; Lao XM; Xu L; Lin XJ; Wang HY; Li SP
BMC Cancer; 2015 Feb; 15():64. PubMed ID: 25880914
[TBL] [Abstract][Full Text] [Related]
33. miR-194 as a predictor for adenoma recurrence in patients with advanced colorectal adenoma after polypectomy.
Wang ZH; Ren LL; Zheng P; Zheng HM; Yu YN; Wang JL; Lin YW; Chen YX; Ge ZZ; Chen XY; Hong J; Fang JY
Cancer Prev Res (Phila); 2014 Jun; 7(6):607-16. PubMed ID: 24691499
[TBL] [Abstract][Full Text] [Related]
34. High miR-96 levels in colorectal adenocarcinoma predict poor prognosis, particularly in patients without distant metastasis at the time of initial diagnosis.
Rapti SM; Kontos CK; Papadopoulos IN; Scorilas A
Tumour Biol; 2016 Sep; 37(9):11815-11824. PubMed ID: 27044381
[TBL] [Abstract][Full Text] [Related]
35. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy.
Cheng G
Adv Drug Deliv Rev; 2015 Jan; 81():75-93. PubMed ID: 25220354
[TBL] [Abstract][Full Text] [Related]
36. Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients.
Summerer I; Unger K; Braselmann H; Schuettrumpf L; Maihoefer C; Baumeister P; Kirchner T; Niyazi M; Sage E; Specht HM; Multhoff G; Moertl S; Belka C; Zitzelsberger H
Br J Cancer; 2015 Jun; 113(1):76-82. PubMed ID: 26057452
[TBL] [Abstract][Full Text] [Related]
37. [Circulating MicroRNAs as Biomarkers of Colorectal Cancer].
Umemura T; Kuroki C
Rinsho Byori; 2015 Mar; 63(3):336-46. PubMed ID: 26524857
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA and targeted mRNA expression profiling analysis in human colorectal adenomas and adenocarcinomas.
Gattolliat CH; Uguen A; Pesson M; Trillet K; Simon B; Doucet L; Robaszkiewicz M; Corcos L
Eur J Cancer; 2015 Feb; 51(3):409-20. PubMed ID: 25586944
[TBL] [Abstract][Full Text] [Related]
39. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
[TBL] [Abstract][Full Text] [Related]
40. Assay reproducibility in clinical studies of plasma miRNA.
Rice J; Roberts H; Burton J; Pan J; States V; Rai SN; Galandiuk S
PLoS One; 2015; 10(4):e0121948. PubMed ID: 25853871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
